Story perspectives

Alumis' Psoriasis Drug Success Sparks 115% Stock Surge

1/6/2026

Summary

Alumis' Psoriasis Breakthrough

Alumis’ TYK2 inhibitor envudeucitinib met primary endpoints in phase 3 psoriasis trials, with 65% achieving 90% improvement at Week 24.
More than 40% of participants achieved complete skin clearance.
Following the announcement, Alumis shares surged over 115%.
Alumis plans to file for U.S. FDA approval in late 2026.
Analysts say envudeucitinib could compete with Bristol Myers Squibb’s Sotyktu and Amgen’s Otezla, but regulatory scrutiny and market competition may affect pricing.

Summary

Alumis' Data Surge

Alumis Inc. will report topline data from its Phase 3 ONWARD program for envudeucitinib on January 6, 2026, sparking a 17.33% stock surge.
Alumis Inc. will hold a conference call to discuss results, boosting investor optimism.
Other biotech firms, including Genelux Corp. and Bright Minds Biosciences, rose after positive trial updates.
Alpha Tau Medical submitted a pre-market approval application to the FDA for treating recurrent cutaneous squamous cell carcinoma.

1 of 2

Alumis' Psoriasis Breakthrough

Alumis’ TYK2 inhibitor envudeucitinib met primary endpoints in phase 3 psoriasis trials, with 65% achieving 90% improvement at Week 24.
More than 40% of participants achieved complete skin clearance.
Following the announcement, Alumis shares surged over 115%.
Alumis plans to file for U.S. FDA approval in late 2026.
Analysts say envudeucitinib could compete with Bristol Myers Squibb’s Sotyktu and Amgen’s Otezla, but regulatory scrutiny and market competition may affect pricing.

1 / 2